Total
0
Shares
Izotropic begins FDA approval process for  imaging system
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Therma Bright (THRM) partners with Ridge Global to expand its U.S. and Global reach
  • Therma Bright believes its AcuVidTM COVID-19 Rapid Antigen Saliva Test meets the new March 16 FDA Guidance for test developers
  • Serial testing involves testing the same individual multiple times within a few days and can increase chances of detecting asymptomatic infection
  • Therma Bright is a medical device technology company focused on providing consumers and medical professionals
  • Therma Bright (THRM) is up 7.55 per cent and is trading at C$0.57 at 12:09 pm ET

Therma Bright Inc. (THRM) has entered into a business agreement with Ridge Global.

Ridge Global is a consultancy founded by Governor Tom Ridge, the first U.S. Secretary of Homeland Security.

The agreement focuses on supporting Therma bright's reach across the United States and the Global marketplace business community and extending policy advisory services in the U.S.

"We're excited to add Ridge Global to our growing advisory team," expressed Rob Fia, CEO of Therma Bright.

"Governor Ridge will serve as a Senior Advisor and support his team in corporate strategy and business development on behalf of Therma Bright," added Fia.

Therma Bright believes its AcuVidTM COVID-19 Rapid Antigen Saliva Test ideally meets the new March 16 FDA Guidance for test developers seeking emergency use authorization (EUA) of certain tests for screening with serial testing.

Serial testing involves testing the same individual multiple times within a few days. It can increase the chances of detecting asymptomatic infections that might not always show up with a single test.

CDC recommends serial testing at least once per week, along with other mitigation measures, such as masking and social distancing, to reduce disease transmission.

Also, with the recent American Rescue Bill passed by President Biden, there are opportunities to assist the U.S. and its citizens detect, contain and mitigate COVID-19, and its growing variants with Therma Bright's AcuVidTM COVID-19 Rapid Antigen Saliva Test once approved under the Emergency Use Authorization (EUA) by the FDA.

Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.

Therma Bright is a medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs.

Therma Bright (THRM) is up 7.55 per cent and is trading at C$0.57 at 12:09 pm ET.

More From The Market Herald
Neovasc’s (TSX:NVCN) Reducer receives first national European reimbursement

" Neovasc (TSX:NVCN) announces FDA approval of clinical trial

Neovasc (NVCN) has received approval from the FDA for the Investigational Device Exemption regarding its COSIRA-II IDE Clinical Trial.
Relay Medical (CSE:RELA) & Fio to provide rapid COVID-19 testing at TIFF

" ScreenPro (CSE:SCRN) providing COVID-19 testing at TIFF

ScreenPro (SCRN) is providing COVID-19 testing services at this year’s Toronto International Film Festival.
Aurora Spine Corporation (TSXV:ASG) announces $6.5 million private placement

" Aurora Spine Corporation (TSXV:ASG) announces $6.5 million private placement

Aurora Spine Corporation (ASG) has announced a C$6.5 million private placement with institutional investors.
VitalHub (TSXV:VHI) signs multi-year contract with Hampshire Hospitals NHS Foundation Trust

" Skylight Health Group (TSXV:SLHG) acquires Pennsylvania Clinic Group

Skylight Health Group Inc. (SLHG) executes the definitive agreements to acquire a controlling interest in Aspire Health Concepts, Inc.